ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 83 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $755,343 | -29.0% | 124,850 | -8.9% | 0.00% | 0.0% |
| Q2 2023 | $1,063,353 | +17.8% | 137,030 | -13.5% | 0.00% | 0.0% |
| Q1 2023 | $903,051 | +494.1% | 158,430 | +233.7% | 0.00% | – |
| Q3 2022 | $152,000 | -29.3% | 47,479 | -1.0% | 0.00% | – |
| Q2 2022 | $215,000 | +35.2% | 47,958 | +0.1% | 0.00% | – |
| Q1 2022 | $159,000 | -99.4% | 47,919 | -97.3% | 0.00% | -100.0% |
| Q4 2021 | $26,544,000 | -17.9% | 1,805,717 | +16.8% | 0.02% | -25.0% |
| Q3 2021 | $32,334,000 | +40.1% | 1,546,323 | +18.6% | 0.03% | +45.5% |
| Q2 2021 | $23,074,000 | -14.8% | 1,304,360 | +18.0% | 0.02% | -21.4% |
| Q1 2021 | $27,082,000 | -27.3% | 1,105,374 | +0.5% | 0.03% | -31.7% |
| Q4 2020 | $37,245,000 | +66.0% | 1,100,293 | +22.6% | 0.04% | +41.4% |
| Q3 2020 | $22,437,000 | +17.1% | 897,134 | +57.9% | 0.03% | +11.5% |
| Q2 2020 | $19,162,000 | – | 568,120 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |